SCHEMBL5523958

SCHEMBL5523958

COc1nc(OC)c(Cl)c(-c2nc3cnc(Nc4ccc(N5CCOCC5)cc4)nc3n(C)c2=O)c1Cl

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FGFR1 P11362 3/20 0.58
SRC P12931 2/20 0.58
PDGFRB P09619 1/20 0.58
SLC2A1 P11166 1/20 0.58
PDGFRA P16234 1/20 0.58
PKMYT1 Q99640 1/20 0.58
CYP1A2 P05177 8/20 0.50
ALDH1A1 P00352 6/20 0.50
CASP7 P55210 6/20 0.49
CASP1 P29466 5/20 0.49
HIF1A Q16665 3/20 0.49
CYP3A4 P08684 3/20 0.49
CYP2C9 P11712 2/20 0.49
CDK4 P11802 4/20 0.49
CCND1 P24385 4/20 0.49
CDK6 Q00534 2/20 0.49
CCND3 P30281 3/20 0.49
CCND2 P30279 2/20 0.49
WEE1 P30291 1/20 0.49
USP2 O75604 4/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5633975 0.87 FGFR1 (0.60) FGFR1SRCPDGFRBSLC2A1PDGFRA
SCHEMBL5523042 0.85 SRC (0.74) FGFR1SRCPDGFRBSLC2A1PDGFRA
SCHEMBL5520408 0.85 FGFR1 (0.64) FGFR1SRCPDGFRBSLC2A1PDGFRA
SCHEMBL5511668 0.84 SRC (0.62) FGFR1SRCPDGFRBSLC2A1PDGFRA
SCHEMBL5516295 0.82 FGFR1 (0.56) FGFR1SRCPDGFRBSLC2A1PDGFRA
SCHEMBL5534904 0.81 CYP1A2 (0.74) FGFR1SRCPDGFRBSLC2A1PDGFRA
SCHEMBL5516251 0.79 FGFR1 (0.58) FGFR1SRCPDGFRBPDGFRACYP1A2
SCHEMBL5520692 0.78 RIPK2 (0.62) FGFR1SRCPDGFRBSLC2A1PDGFRA
SCHEMBL14594126 0.73 FGFR1 (0.54) FGFR1SRCPDGFRBPDGFRACYP1A2
SCHEMBL3458816 0.73 SRC (1.00) FGFR1SRCPDGFRBSLC2A1PDGFRA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7169778-B2 Pteridinones as kinase inhibitors WARNER-LAMBERT COMPANY (US) 2007-01-30 US claimed
EP-1409487-A1 PTERIDINONES AS KINASE INHIBITORS WARNER-LAMBERT COMPANY LLC (US) 2004-04-21 EP claimed
US-20030130286-A1 Pteridinones as kinase inhibitors DENNY WILLIAM ALEXANDER (NZ) 2003-07-10 US claimed
WO-2001019825-A1 PTERIDINONES AS KINASE INHIBITORS WARNER-LAMBERT COMPANY (US) 2001-03-22 WO claimed
US-20070049600-A1 PTERIDINONES AS KINASE INHIBITORS WARNER-LAMBERT COMPANY 2007-03-01 US disclosed
US-20070049600-A1 PTERIDINONES AS KINASE INHIBITORS WARNER-LAMBERT COMPANY 2007-03-01 US disclosed
US-20070049600-A1 PTERIDINONES AS KINASE INHIBITORS WARNER-LAMBERT COMPANY 2007-03-01 US disclosed
US-7169778-B2 Pteridinones as kinase inhibitors WARNER-LAMBERT COMPANY (US) 2007-01-30 US disclosed
US-7169778-B2 Pteridinones as kinase inhibitors WARNER-LAMBERT COMPANY (US) 2007-01-30 US disclosed
US-20030130286-A1 Pteridinones as kinase inhibitors DENNY WILLIAM ALEXANDER (NZ) 2003-07-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030130286-A1 Pteridinones as kinase inhibitors CCNI, CCNK, CDK2 FGFR1 91/4885SRC 1164/4885PDGFRB 281/4885
US-20070049600-A1 PTERIDINONES AS KINASE INHIBITORS CCNI, CCNK, CDK2 FGFR1 50/4885SRC 579/4885PDGFRB 137/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.